Novaestiq Corp., a growth-oriented, aesthetic company focused on aesthetic and medical dermatological product innovations for practices and patients, announced it's definitive agreement with Croma-Pharma GmbH to be the exclusive U.S. distributor of the Saypha line of dermal fillers. Novaestiq has an existing collaboration with Croma-Pharma to develop next-generation dermal fillers utilizing novel cross-linking capabilities.
Related: Movers & Shakers: 3 Industry Updates from PatientNow, DermaTouch and More
Novaestiq also announced that it's currently in exclusive negotiations to combine with Coronado Aesthetics, LLC. Coronado's signature products, Sebacia, FDA-cleared gold microparticles, indicated for use with 1064 nm lasers to treat acne vulgaris and a first-in-class FDA-cleared silver photo-particle topical gel indicated for use with 810 nm diode lasers for removal of light-colored hair will be branded under the Novaestiq aestheticIQ intelligence platform and launched later this year. This combined offering will allow Novaestiq to cater to a significant segment of the U.S. aesthetics market in addition to supporting improved practice economics.
"These pivotal developments signify our transition into a multi-product and practice-centric aesthetic company dedicated to customer excellence," shared Miles Harrison, Co-Founder, CEO & President. "With an expanded portfolio including two FDA-cleared products, two pending FDA submissions, and two candidates approaching Phase 3 trials, Novaestiq is set to realize its vision of Aesthetics for All."
Humberto C. Antunes, Chairman of Novaestiq and Partner at Gore Range Capital, remarked, "Novaestiq's ambition to offer innovative, safe, and efficacious products is commendable. Their world-class leadership combined with a market eager for fresh ideas will position Novaestiq as a significant contributor in the aesthetics industry."
Andreas Prinz, Managing Director, Croma-Pharma shared that "Novaestiq's exceptional leadership brings proven commercial capabilities in aesthetics, which makes them an ideal partner to develop and commercialize our strong pipeline of HA Fillers in the US market."
